Bupivacaine - Liquidia Technologies

Drug Profile

Bupivacaine - Liquidia Technologies

Alternative Names: LIQ865A; LIQ865A bupivacaine formulation; LIQ865B; LIQ865B bupivacaine formulation

Latest Information Update: 01 Feb 2017

Price : $50

At a glance

  • Originator Liquidia Technologies
  • Class Analgesics; Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Postoperative pain

Most Recent Events

  • 01 Feb 2017 Chemical structure information added
  • 21 Dec 2016 Liquidia Technologies plans a phase I trial for in Post-operative pain in Denmark (NCT02982889)
  • 05 Oct 2016 Preclinical trials in Post-operative pain (In volunteers, In adults) in Denmark (SC) (Liquidia Technologies presentation, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top